It was recently shown that EMT occurring in peritoneal, kidney and lung fibrosis, as well as in breast cancer stem cells, was associated with increased p–C-Raf expression13–15, whereby suggesting a rationale for the development of C-Raf inhibitors in fibrosis treatment. Here, RAF1 is linked to pulmonary fibrosis.